Dopamine receptor

Subtypes

The existence of multiple types of receptors for dopamine was first proposed in 1976. There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3, and D4 receptors are members of the D2-like family. There is also some evidence that suggests the existence of possible D6 and D7 dopamine receptors, but such receptors have not been conclusively identified.

At a global level, D1 receptors have widespread expression throughout the brain. The relative amount of DA receptors is in the following order: D1 D2 D3 D5 D4. D1-2 receptor subtypes are found at 10–100 times the levels of the D3-5 subtypes.

D₁-like family

The D1-like family receptors are coupled to the G protein Gsα. D1 is also coupled to Golf.

Gsα subsequently activates adenylyl cyclase, increasing the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP).

• D1 is encoded by the Dopamine receptor D1 gene ().
• D5 is encoded by the Dopamine receptor D5 gene ().

D₂-like family

The D2-like family receptors are coupled to the G protein Giα, which directly inhibits the formation of cAMP by inhibiting the enzyme adenylyl cyclase.

• D2 is encoded by the Dopamine receptor D2 gene (), of which there are two forms: D2Sh (short) and D2Lh (long):
  • The D2Sh form is pre-synaptically situated, having modulatory functions (viz., autoreceptors, which regulate neurotransmission via feedback mechanisms. It affects synthesis, storage, and release of dopamine into the synaptic cleft).
  • The D2Lh form may function as a classical post-synaptic receptor, i.e., transmit information (in either an excitatory or an inhibitory fashion) unless blocked by a receptor antagonist or a synthetic partial agonist.
• D3 is encoded by the Dopamine receptor D3 gene (). Maximum expression of dopamine D3 receptors is noted in the islands of Calleja and nucleus accumbens.
• D4 is encoded by the Dopamine receptor D4 gene (). The D4 receptor gene displays polymorphisms that differ in a variable number tandem repeat present within the coding sequence of exon 3. Some of these alleles are associated with greater incidence of certain disorders. For example, the D4.7 alleles have an established association with attention-deficit hyperactivity disorder.

Receptor heteromers

Dopamine receptors have been shown to heteromerize with a number of other G protein-coupled receptors. Especially the D2 receptor is considered a major hub within the GPCR heteromer network. Protomers consist of

Isoreceptors

• D1–D2
• D1–D3
• D2–D3
• D2–D4
• D2–D5

Non-isoreceptors

• D1–adenosine A1
• D2–adenosine A2A
• D2–ghrelin receptor
• D2sh–TAAR1 (an autoreceptor heteromer)
• D4–adrenoceptor α1B
• D4–adrenoceptor β1

Signalling mechanism

Dopamine receptor D1 and Dopamine receptor D5 are Gs coupled receptors that stimulate adenylyl cyclase to produce cAMP, which in turn increases intracellular calcium and mediates a number of other functions. The D2 class of receptors produce the opposite effect, as they are Gαi and/or Gαo coupled receptors, which blocks the activity of adenylyl cyclase. cAMP mediated protein kinase A activity also results in the phosphorylation of DARPP-32, an inhibitor of protein phosphatase 1. Sustained D1 receptor activity is kept in check by Cyclin-dependent kinase 5. Dopamine receptor activation of Ca2+/calmodulin-dependent protein kinase II can be cAMP dependent or independent.

The cAMP mediated pathway results in amplification of PKA phosphorylation activity, which is normally kept in equilibrium by PP1. The DARPP-32 mediated PP1 inhibition amplifies PKA phosphorylation of AMPA, NMDA, and inward rectifying potassium channels, increasing AMPA and NMDA currents while decreasing potassium conductance.

cAMP independent

D1 receptor agonism and D2 receptor blockade also increases mRNA translation by phosphorylating ribosomal protein s6, resulting in activation of mTOR. The behavioural implications are unknown. Dopamine receptors may also regulate ion channels and BDNF independent of cAMP, possibly through direct interactions. There is evidence that D1 receptor agonism regulates phospholipase C independent of cAMP, however implications and mechanisms remain poorly understood. D2 receptor signalling may mediate protein kinase B, arrestin beta 2, and GSK-3 activity, and inhibition of these proteins results in stunting of the hyperlocomotion in amphetamine treated rats. Dopamine receptors can also transactivate Receptor tyrosine kinases.

Beta Arrestin recruitment is mediated by G-protein kinases that phosphorylate and inactivate dopamine receptors after stimulation. While beta arrestin plays a role in receptor desensitization, it may also be critical in mediating downstream effects of dopamine receptors. Beta arrestin has been shown to form complexes with MAP kinase, leading to activation of extracellular signal-regulated kinases. Furthermore, this pathway has been demonstrated to be involved in the locomotor response mediated by dopamine receptor D1. Dopamine receptor D2 stimulation results in the formation of an Akt/Beta-arrestin/PP2A protein complex that inhibits Akt through PP2A phosphorylation, therefore disinhibiting GSK-3.

Role in the central nervous system

Dopamine receptors control neural signalling that modulates many important behaviours, such as spatial working memory. Dopamine also plays an important role in the reward system, incentive salience, cognition, prolactin release, emesis, and motor function.

Non-CNS dopamine receptors

Cardio-pulmonary system

In humans, the pulmonary artery expresses D1, D2, D4, and D5 and receptor subtypes, which may account for vasodilatory effects of dopamine in the blood. Such receptor subtypes have also been discovered in the epicardium, myocardium, and endocardium of the heart. In rats, D1-like receptors are present on the smooth muscle of the blood vessels in most major organs.

D4 receptors have been identified in the atria of rat and human hearts. Dopamine increases myocardial contractility and cardiac output, without changing heart rate, by signalling through dopamine receptors.

Renal system

Dopamine receptors are present along the nephron in the kidney, with proximal tubule epithelial cells showing the highest density. In rats, D1-like receptors are present on the juxtaglomerular apparatus and on renal tubules, while D2-like receptors are present on the glomeruli, zona glomerulosa cells of the adrenal cortex, renal tubules, and postganglionic sympathetic nerve terminals. Dopamine signalling affects diuresis and natriuresis.

Pancreas

The role of the pancreas is to secrete digestive enzymes via exocrine glands and hormones via endocrine glands. Pancreatic endocrine glands, composed of dense clusters of cells called the Islets of Langerhans, secrete insulin, glucagon, and other hormones essential for metabolism and glycemic control. Insulin secreting beta cells have been intensely researched due to their role in diabetes.

Recent studies have found that beta cells, as well as other endocrine and exocrine pancreatic cells, express D2 receptors and that beta cells co-secrete dopamine along with insulin. Dopamine has been purported to be a negative regulator of insulin, meaning that bound D2 receptors inhibit insulin secretion. The connection between dopamine and beta cells was discovered, in part, due to the metabolic side-effects of certain antipsychotic medications. Traditional/typical antipsychotic medications function by altering the dopamine pathway in the brain, such as blocking D2 receptors. Common side effects of these medications include rapid weight gain and glycemic dysregulation, among others. The effects of these medications are not limited to the brain, so off-target effects in other organs such as the pancreas have been proposed as a possible mechanism.

Adipose tissue

Dopamine receptors D1, D2, D4, and D5 are present in human subcutaneous, visceral, and brown adipose tissue, and have been implicated in lipid and glucose metabolism, and thermogenesis. Dopamine that reaches dopamine receptors in adipose tissue can originate from multiple sources: from the circulation, sympathetic nerves innervating adipose tissue that release dopamine from nerve terminals, local synthesis, or immune cells

In disease

Dysfunction of dopaminergic neurotransmission in the CNS has been implicated in a variety of neuropsychiatric disorders, including social phobia, Tourette's syndrome, Parkinson's disease, schizophrenia, neuroleptic malignant syndrome, attention-deficit hyperactivity disorder (ADHD), and drug and alcohol dependence.

Attention-deficit hyperactivity disorder

Main article: Attention-deficit hyperactivity disorder

Dopamine receptors have been recognized as important components in the mechanism of ADHD for many years. Drugs used to treat ADHD, including methylphenidate and amphetamine, have significant effects on neuronal dopamine signalling. Studies of gene association have implicated several genes within dopamine signalling pathways; in particular, the D4.7 variant of D4 has been consistently shown to be more frequent in ADHD patients. ADHD patients with the 4.7 allele also tend to have better cognitive performance and long-term outcomes compared to ADHD patients without the 4.7 allele, suggesting that the allele is associated with a more benign form of ADHD.

The D4.7 allele has suppressed gene expression compared to other variants.

Addictive drugs

Main article: Addiction

Dopamine is the primary neurotransmitter involved in the reward and reinforcement (mesolimbic) pathway in the brain. Although it was a long-held belief that dopamine was the cause of pleasurable sensations such as euphoria, many studies and experiments on the subject have demonstrated that this is not the case; rather, dopamine in the mesolimbic pathway is responsible for behaviour reinforcement ("wanting") without producing any "liking" sensation on its own. Mesolimbic dopamine and its related receptors are a primary mechanism through which drug-seeking behaviour develops (Incentive Salience), and many recreational drugs, such as cocaine and substituted amphetamines, inhibit the dopamine transporter (DAT), the protein responsible for removing dopamine from the neural synapse. When DAT activity is blocked, the synapse floods with dopamine and increases dopaminergic signalling. When this occurs, particularly in the nucleus accumbens, increased D1 and decreased D2 receptor signalling mediates the "incentive salience" factor and can significantly increase positive associations with the drug in the brain.

Pathological gambling

Main article: Problem gambling

Pathological gambling is classified as a mental health disorder that has been linked to obsessive-compulsive spectrum disorder and behavioural addiction. Dopamine has been associated with reward and reinforcement in relation to behaviors and drug addiction. The role between dopamine and pathological gambling may be a link between cerebrospinal fluid measures of dopamine and dopamine metabolites in pathological gambling. Molecular genetic study shows that pathological gambling is associated with the TaqA1 allele of the Dopamine Receptor D2 (DRD2) dopamine receptor. Furthermore, TaqA1 allele is associated with other reward and reinforcement disorders, such as substance abuse and other psychiatric disorders. Reviews of these studies suggest that pathological gambling and dopamine are linked; however, the studies that succeed in controlling for race or ethnicity, and obtain DSM-IV diagnoses do not show a relationship between TaqA1 allelic frequencies and the diagnostic of pathological gambling.

Schizophrenia

Main article: Dopamine hypothesis of schizophrenia

While there is evidence that the dopamine system is involved in schizophrenia, the theory that hyperactive dopaminergic signal transduction induces the disease is controversial. Psychostimulants, such as amphetamine and cocaine, indirectly increase dopamine signalling; large doses and prolonged use can induce symptoms that resemble schizophrenia. Additionally, many antipsychotic drugs target dopamine receptors, especially D2 receptors.

Genetic hypertension

Dopamine receptor mutations can cause genetic hypertension in humans. This can occur in animal models and humans with defective dopamine receptor activity, particularly D1.

Parkinson's disease

Parkinson's disease is associated with the loss of cells responsible for dopamine synthesis and other neurodegenerative events. Parkinson's disease patients are treated with medications which help to replenish dopamine availability, allowing relatively normal brain function and neurotransmission. Research shows that Parkinson's disease is linked to the class of dopamine agonists instead of specific agents. Reviews touch upon the need to control and regulate dopamine doses for Parkinson's patients with a history of addiction, and those with variable tolerance or sensitivity to dopamine.

Dopamine regulation

Dopamine receptors are typically stable, however sharp (and sometimes prolonged) increases or decreases in dopamine levels can downregulate (reduce the numbers of) or upregulate (increase the numbers of) dopamine receptors.

Haloperidol, and some other antipsychotics, have been shown to increase the binding capacity of the D2 receptor when used over long periods of time (i.e. increasing the number of such receptors). Haloperidol increased the number of binding sites by 98% above baseline in the worst cases, and yielded significant dyskinesia side effects.

Addictive stimuli have variable effects on dopamine receptors, depending on the particular stimulus. According to one study, cocaine, opioids like heroin, amphetamine, alcohol, and nicotine cause decreases in D2 receptor quantity. A similar association has been linked to food addiction, with a low availability of dopamine receptors present in people with greater food intake. A recent news article summarized a U.S. DOE Brookhaven National Laboratory study showing that increasing dopamine receptors with genetic therapy temporarily decreased cocaine consumption by up to 75%. The treatment was effective for 6 days. Cocaine upregulates D3 receptors in the nucleus accumbens, further reinforcing drug seeking behaviour. and Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain, Caffeine, or other more selective adenosine A2A receptor antagonists, causes significantly less motor stimulation in dopamine D2 receptor.

Certain stimulants will enhance cognition in the general population (e.g., direct or indirect mesocortical DRD1 agonists as a class), but only when used at low (therapeutic) concentrations. Relatively high doses of dopaminergic stimulants will result in cognitive deficits.

References

References

1. (June 2010). "The dopamine D4 receptor: biochemical and signalling properties". Cellular and Molecular Life Sciences.
2. (2004). "The neurobiology of dopamine signaling". Arch. Neurol..
3. (1976). "Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data". [[Psychopharmacologia]].
4. (2014). "Alexander Rudolf Cools (1942-2013)". Psychopharmacology.
5. (2002). "Dopamine, hypertension and obesity". J Hum Hypertens.
6. (2018-01-01). "Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease". Journal of Experimental Neuroscience.
7. (2006). "What has been learnt from study of dopamine receptors in Parkinson's disease?". Pharmacol. Ther..
8. (August 2004). "Dopamine receptor signaling". Journal of Receptor and Signal Transduction Research.
9. (2002). "G protein pathways". Science.
10. ["Introduction to Neuroscience"](https://books.google.com/books?id=jXnkai44PxYC&q=The+D2Sh+form+is+pre-synaptically+situated,+having+modulatory+functions+(viz.,+autoreceptors,+which+regulate+neurotransmission+by+feed-back+mechanisms,+affecting+synthesis,+storage,+and+release+of+dopamine+into+the+synaptic+cleft&pg=PA90).
11. (1998). "D3 dopamine receptor mRNA is widely expressed in the human brain". Brain Res..
12. [https://www.ncbi.nlm.nih.gov/gene/1815?ordinalpos=2&itool=EntrezSystem2.PEntrez.Gene.Gene_ResultsPanel.Gene_RVDocSum#geneReference%20Sequences NCBI Database]
13. (2002). "The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA)". Mol. Psychiatry.
14. (2004). "Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD". Am J Psychiatry.
15. (2004). "Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5". Mol. Psychiatry.
16. (2015). "Dopamine receptors – IUPHAR Review 13". Br. J. Pharmacol..
17. (May 2014). "The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components". Int J Mol Sci.
18. (January 2016). "Role of iso-receptors in receptor-receptor interactions with a focus on dopamine iso-receptor complexes". Rev Neurosci.
19. (January 2015). "Dopamine receptors – IUPHAR Review 13". British Journal of Pharmacology.
20. (2011). "Role of Beta-arrestin 2 downstream of dopamine receptors in the Basal Ganglia". Frontiers in Neuroanatomy.
21. (2006). "Under the curve: critical issues for elucidating D1 receptor function in working memory". Neuroscience.
22. Webster, Roy. (2001). "Neurotransmitters, drugs and brain function". Wiley.
23. (2006). "Dopamine receptor subtypes in the human pulmonary arterial tree". Autonomic and Autacoid Pharmacology.
24. (2010). "Dopamine receptor subtypes in the native human heart". Heart and Vessels.
25. (2003). "Renal dopamine receptors and hypertension". Exp. Biol. Med. (Maywood).
26. (1998). "Pharmacological characterization and autoradiographic localization of a putative dopamine D4 receptor in the heart". J Auton Pharmacol.
27. Leung, Po Sing. (2010). "Overview of the Pancreas". Springer Netherlands.
28. (January 2019). "Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention". Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
29. (November 2005). "Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion". Journal of Biological Chemistry.
30. (November 2005). "Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion". Journal of Biological Chemistry.
31. (2020-04-07). "D2-Like Receptors Mediate Dopamine-Inhibited Insulin Secretion via Ion Channels in Rat Pancreatic β-Cells". Frontiers in Endocrinology.
32. (2021-02-16). "Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors". Translational Psychiatry.
33. (August 2020). "Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology". Neuropharmacology.
34. (2010-03-01). "Adverse effects of antipsychotic medications". American Family Physician.
35. Nadal, Roser. (September 2001). "Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D 2 Receptor Antagonist". CNS Drug Reviews.
36. (2010-09-15). "Past and Present Progress in the Pharmacologic Treatment of Schizophrenia". The Journal of Clinical Psychiatry.
37. (2019-01-18). "Current Views on Dopaminergic Drugs Affecting Glucose Homeostasis". Current Diabetes Reviews.
38. (26 September 2011). "Dopamine Receptors in Human Adipocytes: Expression and Functions". PLOS ONE.
39. (1 February 2024). "Subcutaneous adipose tissue dopamine D2 receptor is increased in prediabetes and T2D". Endocrine.
40. (January 2023). "Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue". International Journal of Molecular Sciences.
41. (20 November 2011). "Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis". Nature.
42. (2000). "Low dopamine D(2) receptor binding potential in social phobia". Am J Psychiatry.
43. (2006). "Dopamine and the diseased brain". CNS Neurol Disord Drug Targets.
44. (2006). "Parkinson's Disease and Related Disorders". J. Neural Transm. Suppl..
45. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome". Am. J. Med. Genet. B Neuropsychiatr. Genet..
46. (2006). "Candidate gene studies of attention-deficit/hyperactivity disorder". J Clin Psychiatry.
47. (2007). "Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyperactivity disorder (ADHD): an update". Am. J. Med. Genet. B Neuropsychiatr. Genet..
48. (2003). "The human dopamine D4 receptor repeat sequences modulate expression". Pharmacogenomics J..
49. (1998). "What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?". Brain Research. Brain Research Reviews.
50. (2012). "The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers". PLOS ONE.
51. (2018). "Current perspectives on incentive salience and applications to clinical disorders". Current Opinion in Behavioral Sciences.
52. (2022-03-22). "Drugs and the Brain".
53. (2004). "Dopamine and drug addiction: the nucleus accumbens shell connection". Neuropharmacology.
54. (2002). "D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action". J. Cell. Physiol..
55. (October 2008). "Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.
56. (October 1999). "Gender differences in major depressive disorder and bipolar disorder". CNS Spectrums.
57. (2003). "Regulation of blood pressure by dopamine receptors". Nephron Physiol.
58. (May 2004). "Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough". The Lancet. Neurology.
59. (1 January 2004). "Molecular mechanisms of drug addiction". Neuropharmacology.
60. Scheler, G.. (2004). "Regulation of neuromodulator receptor efficacy--implications for whole-neuron and synaptic plasticity.". Prog. Neurobiol..
61. (2000). "Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study". Psychopharmacology.
62. (December 2011). "Natural rewards, neuroplasticity, and non-drug addictions". Neuropharmacology.
63. (April 2008). "Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse". The American Journal of Psychiatry.
64. Park, Paul. (9 August 2007). "Food Addiction: From Drugs to Donuts, Brain Activity May be the Key". DocShop.
65. (May 2010). "Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats". Nature Neuroscience.
66. (18 April 2008). "Gene Therapy For Addiction: Flooding Brain With 'Pleasure Chemical' Receptors Works On Cocaine, As On Alcohol".
67. (October 1996). "Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities". The Journal of Neuroscience.
68. (2015-04-14). "Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain". Translational Psychiatry.
69. (2014). "Molecular and pharmacodynamic interactions between caffeine and dopaminergic system". Journal of Medicine and Life.
70. (January 2015). "Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis". J. Cogn. Neurosci..
71. (January 2014). "Psychostimulants and cognition: a continuum of behavioral and cognitive activation". Pharmacol. Rev..
72. (2009). "Molecular Neuropharmacology: A Foundation for Clinical Neuroscience". McGraw-Hill Medical.
73. and